Cover Image
市場調查報告書

糖尿病的印度市場調查、分析

Indian Diabetes Market Research and Analysis, 2015-2022

出版商 Orion Market Research Pvt Ltd 商品編碼 505702
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病的印度市場調查、分析 Indian Diabetes Market Research and Analysis, 2015-2022
出版日期: 2017年05月10日 內容資訊: 英文
簡介

本報告提供印度的糖尿病市場相關分析,市場概要,法規情形,主要的促進、阻礙因素,各產品、用途、終端用戶、地區的市場趨勢預測,最新的市場競爭情形,主要企業簡介、最新趨勢等調查。

第1章 調查摘要

第2章 市場概要、考察

  • 定義
  • 分析師的見解與目前市場趨勢
    • 主要調查結果
    • 建議
    • 結論
  • 法規

第3章 市場決策要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 市場區隔

  • 印度的糖尿病市場:各產品
    • 第一型糖尿病
    • 第二型糖尿病
    • 腸胃科
  • 印度的糖尿病市場:各用途
    • Alpha Glucosidase抑制劑
    • Amylin類比
    • 抗糖尿病混合藥
    • Dipeptidyl Peptidase4抑制劑
    • 腸泌素類似藥物
    • 胰島素
    • Meglitinides
    • 非磺醯尿素類
    • SGLT-2 抑制劑
    • 磺醯尿素類
    • 胰島素增敏劑
  • 印度的糖尿病市場:各終端用戶
    • 血糖儀表
    • 血糖片
    • 胰島素注射筆
    • 胰島素注射器
    • 持續葡萄糖監控系統
    • 胰島素幫浦
    • 採血針

第5章 競爭環境

  • 主要策略分析
  • 主要企業分析

第6章 企業簡介

目錄
Product Code: OMR2017107

Market Insights:

The Indian diabetes market is estimated to grow with the CAGR of 20.5% during the period 2017-2022. The major factors that are augmenting the growth of the market are increase in the geriatric population of the India, urbanization and increasing prevalence of diabetes in the country. Additionally, rising obesity levels, innovation and development of new product for the diagnosis and treatment of diabetes and growing trend of the wearable devices and POC solution are also some of the major factors that are fuelling the growth of the Indian diabetes market.

India has huge potential for the growth of the diabetes market. Diabetes is an expensive and rapidly growing health problem all over the world. In 2015, it is estimated that the approximately 370 million across the globe have diabetes, out of which more than 90% of the population have Type-II diabetes. India has the second largest number of diabetic's population in the world. In 2015, about 60 million people India is suffering from diabetes. Moreover, 75 million people are in the risk to develop diabetes. These are the major factors that are attracting multinational companies to invest in India. Therefore increasing investment by the key players in the India are driving the growth of the diabetes market.

Increasing geriatric population is also one of the major factors driving the growth of the diabetes market in India. In the year 2015, population aging 65 year or older is estimated to account for about 6% of the total population of the India i.e. 78 million, it is further estimated to reach 8.8% by the year 2030. Population aging 65 or older are more prone to diabetes. Therefore increasing geriatric population in India is estimated to motivate the growth of the diabetes market in India.

However, there are certain factors that are affecting the growth of the diabetes market in India. Lack of awareness among people, high cost and recurring cost of treatment, lack of availability of insulin pumps and CGMS devices are some of the major constraints that are hindering the growth of the diabetes market in the region.

Competitive Insights:

Key players of the Indian diabetes market are AstraZeneca Pharma India ltd, Eli Lily and company India ltd, GlaxoSmithKline Pharmaceuticals ltd, Glenmark Pharmaceuticals, Lupin pharmaceuticals ltd, Merck & co, Micro labs Ltd, MSD pharmaceuticals, Novartis India, Novo Nordisk India, Pfizer India, Sanofi Aventis, Sun Pharmaceuticals, USV India.

Market Segments:

  • 1. INDIAN DIABETES MARKET BY TYPE
  • 2. INDIAN DIABETES MARKET BY DRUG CLASS
  • 3. INDIAN DIABETES MARKET BY DEVICES

OMR Report covers:

  • Comprehensive research methodology of Global Indian Diabetes Market
  • This report also includes detailed and extensive market overview with Analyst insights & key market trends.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Indian Diabetes Market
  • Insights about market determinants which are stimulating the Global Indian Diabetes Market
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. INCREASE IN GERIATRIC POPULATION
    • 3.1.2. RISING OBESITY LEVELS
    • 3.1.3. URBANIZATION
    • 3.1.4. INCREASING PREVALENCE OF DIABETES IN INDIA
    • 3.1.5. INNOVATION AND DEVELOPMENT OF NEW PRODUCTS
    • 3.1.6. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
  • 3.2. RESTRAINTS
    • 3.2.1. HIGH AND RECURRING COST OF TREATMENT
    • 3.2.2. LACK OF AWARENESS AMONG PEOPLE
    • 3.2.3. LACK OF AVAILABILITY OF INSULIN PUMPS AND CGMS DEVICES
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING INVESTMENT BY MARKET PLAYERS IN INDIA
    • 3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
    • 3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON INVASIVE MONITORING DEVICES

4. MARKET SEGMENTATION

  • 4.1. INDIAN DIABETES MARKET BY TYPE
    • 4.1.1. TYPE 1 DIABETES MARKET
    • 4.1.2. TYPE 2 DIABETES MARKET
    • 4.1.3. GESTATIONAL
  • 4.2. INDIAN DIABETES MARKET BY DRUG CLASS
    • 4.2.1. ALPHA-GLUCOSIDASE INHIBITORS
    • 4.2.2. AMYLIN ANALOGS
    • 4.2.3. ANTIDIABETIC COMBINATIONS
    • 4.2.4. DIPEPTIDYL PEPTIDASE 4 INHIBITORS
    • 4.2.5. INCRETIN MIMETICS
    • 4.2.6. INSULIN
    • 4.2.7. MEGLITINIDES
    • 4.2.8. NON-SULFONYLUREAS
    • 4.2.9. SGLT-2 INHIBITORS
    • 4.2.10. SULFONYLUREAS
    • 4.2.11. THIAZOLIDINEDIONES
  • 4.3. INDIAN DIABETES MARKET BY DEVICES
    • 4.3.1. BLOOD GLUCOSE METERS
    • 4.3.2. BLOOD GLUCOSE STRIPS
    • 4.3.3. INSULIN INJECTION PENS
    • 4.3.4. INSULIN SYRINGES
    • 4.3.5. CONTINUOUS GLUCOSE MONITORING SYSTEMS
    • 4.3.6. INSULIN PUMPS
    • 4.3.7. LANCETS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGY ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS

6. COMPANY PROFILES

  • 7.1. ASTRAZENECA PHARMA INDIA LTD
    • 7.1.1. INTRODUCTION
    • 7.1.2. ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
    • 7.1.3. ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
  • 7.2. ELI LILY AND COMPANY INDIA LTD
    • 7.2.1. INTRODUCTION
    • 7.2.2. ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
    • 7.2.3. ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
  • 7.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD
    • 7.3.1. INTRODUCTION
    • 7.3.2. GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
    • 7.3.3. GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
  • 7.4. GLENMARK INDIA
    • 7.4.1. INTRODUCTION
    • 7.4.2. GLENMARK INDIA PRODUCT PORTFOLIO
    • 7.4.3. GLENMARK INDIA RECENT ACTIVITIES
  • 7.5. LUPIN PHARMACEUTICALS LTD
    • 7.5.1. INTRODUCTION
    • 7.5.2. LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
    • 7.5.3. LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
  • 7.6. MERCK & CO.
    • 7.6.1. INTRODUCTION
    • 7.6.2. MERCK & CO. PRODUCT PORTFOLIO
    • 7.6.3. MERCK & CO. RECENT ACTIVITIES
  • 7.7. MICRO LABS LTD
    • 7.7.1. INTRODUCTION
    • 7.7.2. MICRO LABS LTD PRODUCT PORTFOLIO
    • 7.7.3. MICRO LABS LTD RECENT ACTIVITIES
  • 7.8. MSD PHARMACEUTICALS
    • 7.8.1. INTRODUCTION
    • 7.8.2. MSD PHARMACEUTICALS PRODUCT PORTFOLIO
    • 7.8.3. MSD PHARMACEUTICALS RECENT ACTIVITIES
  • 7.9. NOVARTIS
    • 7.9.1. INTRODUCTION
    • 7.9.2. NOVARTIS PRODUCT PORTFOLIO
    • 7.9.3. NOVARTIS RECENT ACTIVITIES
  • 7.10. NOVO NORDISK INDIA
    • 7.10.1. INTRODUCTION
    • 7.10.2. NOVO NORDISK INDIA PRODUCT PORTFOLIO
    • 7.10.3. NOVO NORDISK INDIA RECENT ACTIVITIES
  • 7.11. PFIZER INDIA
    • 7.11.1. INTRODUCTION
    • 7.11.2. PFIZER INDIA PRODUCT PORTFOLIO
    • 7.11.3. PFIZER INDIA RECENT ACTIVITIES
  • 7.12. SANOFI INDIA
    • 7.12.1. INTRODUCTION
    • 7.12.2. SANOFI INDIA PRODUCT PORTFOLIO
    • 7.12.3. SANOFI INDIA RECENT ACTIVITIES
  • 7.13. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.13.1. INTRODUCTION
    • 7.13.2. SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
    • 7.13.3. SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
  • 7.14. USV INDIA
    • 7.14.1. INTRODUCTION
    • 7.14.2. USV INDIA PRODUCT PORTFOLIO
    • 7.14.3. USV INDIA RECENT ACTIVITIES

List of Tables

  • TABLE # 1 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY TYPE 2015-2022 ($ MILLION)
  • TABLE # 2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
  • TABLE # 6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 7 INDIAN AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 8 INDIAN ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 9 INDIAN DIPEPTIDYL PEPTIDASE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 10 INDIAN INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 11 INDIAN INSULIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 12 INDIAN MEGLITINIDES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 13 INDIAN NON SULFONYLUREAS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 14 INDIAN THIAZOLIDINEDIONES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 15 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DEVICES, 2015-2022 ($ MILLION)
  • TABLE # 16 INDIAN BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 17 INDIAN BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 18 INDIAN INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 19 INDIAN INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
  • TABLE # 20 INDIAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 21 INDIAN INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 22 INDIAN LANCETS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • TABLE # 23 ASTRAZENECA PHARMA INDIA LTD PRODUCT PORTFOLIO
  • TABLE # 24 ASTRAZENECA PHARMA INDIA LTD RECENT ACTIVITIES
  • TABLE # 25 ELI LILY AND COMPANY INDIA LTD. PRODUCT PORTFOLIO
  • TABLE # 26 ELI LILY AND COMPANY INDIA LTD. RECENT ACTIVITIES
  • TABLE # 27 GLAXOSMITHKLINE PHARMACEUTICALS LTD PRODUCT PORTFOLIO
  • TABLE # 28 GLAXOSMITHKLINE PHARMACEUTICALS LTD RECENT ACTIVITIES
  • TABLE # 29 GLENMARK INDIA PRODUCT PORTFOLIO
  • TABLE # 30 GLENMARK INDIA RECENT ACTIVITIES
  • TABLE # 31 LUPIN PHARMACEUTICALS LTD PRODUCT PORTFOLIO
  • TABLE # 32 LUPIN PHARMACEUTICALS LTD RECENT ACTIVITIES
  • TABLE # 33 MERCK & CO. PRODUCT PORTFOLIO
  • TABLE # 34 MERCK & CO. RECENT ACTIVITIES
  • TABLE # 35 MICRO LABS LTD PRODUCT PORTFOLIO
  • TABLE # 36 MICRO LABS LTD RECENT ACTIVITIES
  • TABLE # 37 MSD PHARMACEUTICALS PRODUCT PORTFOLIO
  • TABLE # 38 MSD PHARMACEUTICALS RECENT ACTIVITIES
  • TABLE # 39 NOVARTIS PRODUCT PORTFOLIO
  • TABLE # 40 NOVARTIS RECENT ACTIVITIES
  • TABLE # 41 NOVO NORDISK INDIA PRODUCT PORTFOLIO
  • TABLE # 42 NOVO NORDISK INDIA RECENT ACTIVITIES
  • TABLE # 43 PFIZER INDIA PRODUCT PORTFOLIO
  • TABLE # 44 PFIZER INDIA RECENT ACTIVITIES
  • TABLE # 45 SANOFI INDIA PRODUCT PORTFOLIO
  • TABLE # 46 SANOFI INDIA RECENT ACTIVITIES
  • TABLE # 47 SUN PHARMACEUTICALS INDUSTRIES LTD PRODUCT PORTFOLIO
  • TABLE # 48 SUN PHARMACEUTICALS INDUSTRIES LTD RECENT ACTIVITIES
  • TABLE # 49 USV INDIA PRODUCT PORTFOLIO
  • TABLE # 50 USV INDIA RECENT ACTIVITIES

List of Figures

  • FIGURE # 1 INDIAN DIABETES PREVALANCE RATE, 2010-2015
  • FIGURE # 2 INDIAN TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • FIGURE # 3 INDIAN TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • FIGURE # 4 INDIAN GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
  • FIGURE # 5 INDIAN DIABETES MARKET RESEARCH AND ANALYSIS, BY DRUG CLASS, 2015-2022 ($ MILLION)
  • FIGURE # 6 INDIAN ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Back to Top